Pulmotect, Inc.
Pulmotect, Inc. is dedicated to harnessing the power of the innate immune system to develop inhaled therapeutics that provide immediate and effective protection against viral, bacterial, and fungal pathogens. Their lead product, PUL-042, has demonstrated safety and efficacy in clinical trials, with ongoing studies to assess its effectiveness in preventing respiratory complications and improving outcomes in at-risk populations.
Industries
Nr. of Employees
small (1-50)
Pulmotect, Inc.
Houston, Texas, United States, North America
Products
Clinical-stage inhaled innate immune stimulant (pulmonary)
A clinical-stage inhaled therapeutic candidate formulated for aerosol or intranasal delivery that activates innate immune defenses in the lungs to reduce susceptibility to viral, bacterial and fungal respiratory infections; demonstrated tolerability in Phase I/IIa trials and exploratory antiviral activity in Phase II studies.
Clinical-stage inhaled innate immune stimulant (pulmonary)
A clinical-stage inhaled therapeutic candidate formulated for aerosol or intranasal delivery that activates innate immune defenses in the lungs to reduce susceptibility to viral, bacterial and fungal respiratory infections; demonstrated tolerability in Phase I/IIa trials and exploratory antiviral activity in Phase II studies.
Expertise Areas
- Clinical trial management for respiratory therapeutics
- Inhaled formulation and aerosol delivery
- Innate immunity–based therapeutic development
- Preclinical infectious disease models
Key Technologies
- Aerosolized/inhalation delivery
- Intranasal spray delivery
- Innate immune stimulation
- Preclinical respiratory infection models